Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer
- PMID: 15193262
- DOI: 10.1016/j.ccr.2004.05.016
Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer
Abstract
Using a novel approach that detects changes in the conformation of ERalpha, we studied the efficacy of anti-estrogens to inactivate ERalpha under different experimental conditions. We show that phosphorylation of serine-305 in the hinge region of ERalpha by protein kinase A (PKA) induced resistance to tamoxifen. Tamoxifen bound but then failed to induce the inactive conformation, invoking ERalpha-dependent transactivation instead. PKA activity thus induces a switch from antagonistic to agonistic effects of tamoxifen on ERalpha. In clinical samples, we found that downregulation of a negative regulator of PKA, PKA-RIalpha, was associated with tamoxifen resistance prior to treatment. Activation of PKA by downregulation of PKA-RIalpha converts tamoxifen from an ERalpha inhibitor into a growth stimulator, without any effect on ICI 182780 (Fulvestrant).
Similar articles
-
MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.Oncogene. 2002 Jun 6;21(25):4000-8. doi: 10.1038/sj.onc.1205506. Oncogene. 2002. PMID: 12037682
-
PKA-induced phosphorylation of ERα at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer.Breast Cancer Res Treat. 2011 Jan;125(1):1-12. doi: 10.1007/s10549-010-0798-y. Epub 2010 Mar 9. Breast Cancer Res Treat. 2011. PMID: 20213082 Clinical Trial.
-
PKA-induced resistance to tamoxifen is associated with an altered orientation of ERalpha towards co-activator SRC-1.EMBO J. 2007 Aug 8;26(15):3534-44. doi: 10.1038/sj.emboj.7601791. Epub 2007 Jul 12. EMBO J. 2007. PMID: 17627277 Free PMC article.
-
Approaches targeted to estrogen receptors for treatment of tamoxifen-resistant breast cancer: a brief overview.Oncology. 2000;59 Suppl 1:3-4. doi: 10.1159/000055280. Oncology. 2000. PMID: 11096349 Review. No abstract available.
-
Insights into how phosphorylation of estrogen receptor at serine 305 modulates tamoxifen activity in breast cancer.Mol Cell Endocrinol. 2019 Mar 1;483:97-101. doi: 10.1016/j.mce.2019.01.014. Epub 2019 Jan 16. Mol Cell Endocrinol. 2019. PMID: 30659843 Free PMC article. Review.
Cited by
-
Application of cAMP-dependent catalytic subunit β (PRKACB) Low Expression in Predicting Worse Overall Survival: A Potential Therapeutic Target for Colorectal Carcinoma.J Cancer. 2020 Jun 7;11(16):4841-4850. doi: 10.7150/jca.46156. eCollection 2020. J Cancer. 2020. PMID: 32626531 Free PMC article.
-
Ubiquitylation of nuclear receptors: new linkages and therapeutic implications.J Mol Endocrinol. 2015 Jun;54(3):R151-67. doi: 10.1530/JME-14-0308. Epub 2015 May 5. J Mol Endocrinol. 2015. PMID: 25943391 Free PMC article. Review.
-
The Estrogen Receptor α-Cistrome Beyond Breast Cancer.Mol Endocrinol. 2016 Oct;30(10):1046-1058. doi: 10.1210/me.2016-1062. Epub 2016 Aug 4. Mol Endocrinol. 2016. PMID: 27489947 Free PMC article. Review.
-
δEF1 down-regulates ER-α expression and confers tamoxifen resistance in breast cancer.PLoS One. 2012;7(12):e52380. doi: 10.1371/journal.pone.0052380. Epub 2012 Dec 21. PLoS One. 2012. PMID: 23285017 Free PMC article.
-
Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?Nat Rev Clin Oncol. 2012 Sep;9(9):529-41. doi: 10.1038/nrclinonc.2012.121. Epub 2012 Jul 24. Nat Rev Clin Oncol. 2012. PMID: 22825374 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases